Dr. Philip A. Friedlander, MD

Dr. Friedlander practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Friedlander's NPI, 1932146677, was assigned on June 1, 2006. Dr. Friedlander graduated from Vagelos College of Physicians and Surgeons in 1999. Dr. Friedlander's New York license number on file is 219507.

Dr. Friedlander's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Friedlander also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Friedlander's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. Dr. Friedlander is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Friedlander to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Friedlander practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Friedlander's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Friedlander is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Friedlander's licenses on file in 4 states: New York, Florida, New Jersey and Massachusetts.

Dmand AI lists lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Friedlander treats.

CMS data shows 495 Medicare services from Dr. Friedlander across 5 procedure codes in 2024, for 169 Medicare patients. Medicare paid $49,603 for them.

CMS counts 169 Medicare patients who saw Dr. Friedlander in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 20% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Friedlander's median patient age at 71, with 43% women.

In 2024, Dr. Friedlander wrote 77 Medicare Part D claims for 12 patients. 34% of them were for generic drugs. CMS names the drug for 63 of them, across 5 drugs with 11 or more claims each, at $590,135 in total drug cost. In 2023, CMS named 26 claims across 2 drugs.

Dr. Friedlander accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Friedlander as offering telehealth.

Dmand AI links 47 papers to Dr. Friedlander, published from 2012 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Melanoma, Skin Neoplasms and Antibodies, Monoclonal. Dr. Friedlander has published most often in J Clin Oncol. Dr. Friedlander's most frequent co-authors are Yvonne M. Saenger, Anne Lynn Su Chang, MD and Michael Robert Migden, MD.

Dmand AI links Dr. Friedlander to 10 clinical trials, 5 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Neoplasm Metastasis. Icahn School of Medicine at Mount Sinai sponsors the most, 2.

CMS Open Payments shows 32 general payments to Dr. Friedlander from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. Sun Pharmaceutical Industries Inc. paid the most, $20,508.

Dmand AI lists 1 award for Dr. Friedlander, most recently CMS Stage 1 EHR in 2013.

Dr. Friedlander graduated from Vagelos College of Physicians and Surgeons in 1999.

Dr. Friedlander is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.